Source: Eur Respir J 2013; 41: 96-103
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Savale Laurent, Magnier Romain, Le Pavec Jérôme, Jaïs Xavier, Montani David, O'Callaghan Dermot S., Humbert Marc, Dingemanse Jasper, Simonneau Gérald, Sitbon Olivier. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41: 96-103

Member's Comments

No comment yet.

Related content which might interest you: Bosentan therapy for portopulmonary hypertension Source: Eur Respir J 2005; 25: 502-508 Year: 2005 Experience with inhaled iloprost and bosentan in portopulmonary hypertension Source: Eur Respir J 2007; 30: 1096-1102 Year: 2007 Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2004; 24: 1007-1010 Year: 2004 Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 92-98 Year: 2009 Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 Source: Eur Respir J 2004; 24: 353-359 Year: 2004 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Sildenafil treatment for portopulmonary hypertension Source: Eur Respir J 2006; 28: 563-567 Year: 2006 Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2006 Oct 01;28(4):691-694 Year: 2006 Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Source: Eur Respir J 2007; 29: 469-475 Year: 2007 Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure Source: Eur Respir J 2011; 37: 578-586 Year: 2011 Pulmonary hypertension in COPD Source: Eur Respir Mon 2013; 59: 189-205 Year: 2013 Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment Year: 2007 Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011 The new clinical trials on pharmacological treatment in pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1037-1049 Year: 2002 The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study Source: Eur Respir J 2006; 28: 138-143 Year: 2006 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017